Artelo Biosciences (<strongNasdaq: ARTL>), a clinical-stage pharmaceutical company, announced positive interim results from its Phase 2 CAReS trial evaluating ART27.13 for cancer anorexia-cachexia syndrome (CACS). The data showed improvements in patient weight, lean body mass, and activity levels.
The positive findings have spurred significant interest from several pharmaceutical companies. This interest, coupled with the promising interim data, has led Artelo to pursue a strategic partnership for the further development of ART27.13.
Gregory D. Gorgas, President and CEO of Artelo, indicated the company believes that licensing ART27.13 to a larger pharmaceutical company is the most efficient and shareholder-friendly approach. He emphasized the significant market opportunity for a successful CACS treatment, given the lack of currently approved therapies.
ART27.13, a novel benzimidazole derivative, is designed for once-daily oral administration. It selectively targets peripheral CB1 and CB2 receptors, aiming to improve body weight, appetite, muscle mass, and overall quality of life in cancer patients. The drug has previously undergone seven clinical studies involving more than 280 participants.
The CAReS (Cancer Appetite Recovery Study) trial is a Phase 1/2 randomized, placebo-controlled study. The Phase 1 portion established the safe and effective dose of ART27.13, while Phase 2 focuses on evaluating the drug’s efficacy in improving lean body mass, weight gain, and appetite compared to a placebo.
CACS is a significant health concern, affecting up to 80% of patients with advanced cancer. It is characterized by appetite loss, weight loss, and muscle and fat breakdown. The condition significantly impacts patient health, often weakening the immune system and diminishing the ability to tolerate cancer treatments. The substantial market potential of a successful CACS treatment is estimated to exceed $3 billion.
Artelo‘s strategy focuses on leveraging the positive ART27.13 data to secure a development partner. This approach aims to expedite the drug’s advancement through registration trials and ultimately bring it to market, addressing a significant unmet medical need in oncology. The company will provide updates on its progress as they become available.
Related
